Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate

Lenart, Brett A.<sup>1</sup>; Lorich, Dean G.<sup>1</sup>; Lane, Joseph M.<sup>1</sup>

Affiliations

¹Weill Cornell Medical College, New York, NY 10021

Links

DOI: 10.1056/NEJMc0707493

PubMed: 18354114

WoS: 000254094400027

Cited Works (1)

Year	Entry
2005	Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. March 2005;90(3):1294-1301.

Cited By (24)

Year	Entry
2010	Gourion-Arsiquaud S, Allen MR, Burr DB, Vashishth D, Tang SY, Boskey AL. Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. Bone. March 2010;46(3):666-672.
2011	Tjhia CK, Odvina CV, Rao DS, Stover SM, Wang X, Fyhrie DP. Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects. Bone. December 2011;49(6):1279-1289.
2014	Bajaj D, Geissler JR, Allen MR, Burr DB, Fritton JC. The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronate. Bone. July 2014;64:57-64.
2021	Unim B, Minelli G, Da Cas R, Manno V, Trotta F, Palmieri L, Galluzzo L, Maggi S, Onder G. Trends in hip and distal femoral fracture rates in Italy from 2007 to 2017. Bone. January 2021;142:115752.
2022	Black DM, Condra K, Adams AL, Eastell R. Bisphosphonates and the risk of atypical femur fractures. Bone. March 2022;156:116297.
2022	Schwartz E, Reichert Z, Van Poznak C. Pharmacologic management of metastatic bone disease. Bone. May 2022;158:115735.
2010	Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MCH, Weinstein RS, Whyte M. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. November 2010;25(11):2267-2294.
2012	Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, Zhou H, Burchette RJ, Ott SM. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. December 2012;27(12):2544-2550.
2023	Kline GA, Morin SN, Lix LM, Leslie WD. A population-based registry study of extended bisphosphonate use: minimal shift after landmark publications about shorter treatment duration. J Bone Miner Res. October 2023;38(10):1435-1442.
2019	Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. May 2019;104(5):1595-1622.
2009	KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Int. August 2009;76(suppl 113):S1-S130.
2011	Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. NEJM. May 5, 2011;364(18):1728-1737.
2009	Boskey AL, Spevak L, Weinstein RS. Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int. May 2009;20(5):793-800.
2017	Lloyd AA, Gludovatz B, Riedel C, Luengo EA, Saiyed R, Marty E, Lorich DG, Lane JM, Ritchie RO, Busse B, Donnelly E. Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance. Proc Natl Acad Sci USA. August 15, 2017;114(33):8722-8727.
2014	Fonseca H, Moreira-Gonçalves D, Coriolano H-JA, Duarte JA. Bone quality: the determinants of bone strength and fragility. Sports Med. January 2014;44(1):37-53.
2020	Mehraban Alvandi L. Diffuse Damage Repair Mechanism in Bone [PhD thesis]. New York, NY: The City College of New York; 2020.
2013	Turnbull TL. The Spatial Distribution of Fatigue Microdamage Accumulation in Cortical Bone and Factors Influencing Fracture Risk [PhD thesis]. University of Notre Dame; July 2013.
2016	Hunckler MD. Investigation of a Rabbit Ulnar Loading Model for Atypical Fractures in Cortical Bone During Long-Term Bisphosphonate Treatment [Master's thesis]. University of Notre Dame; December 2016.
2014	Bradke BS. The Role of Cortical and Cancellous Bone Quality on Vertebral Fragility [PhD thesis]. Troy, NY: Rensselaer Polytechnic Institute; April 2014.
2012	Kwaczala AT. Alendronate and PTH Differentially Modulate Bone Quality and Reduce Adiposity in an OVX Rat Model [PhD thesis]. Stony Brook, NY: Stony Brook University; December 2012.
2018	Pendleton MM. Effects of Spaceflight- and Clinically-Relevant Ionizing Radiation Exposure on Bone Biomechanics [PhD thesis]. Berkeley, CA: Berkeley, University of California; 2018.
2012	Tjhia CKH. Bone Quality of Patients With Atypical Fractures and Severely Suppressed Bone Turnover [PhD thesis]. Davis, University of California; 2012.
2013	Davis MS. Microdamage: Its Role in the Mechanical Integrity of Low Bone Mass Diseases and Its Treatment Implications [PhD thesis]. University of Michigan; 2013.
2015	Ng AH-M. A Mouse Model of Adynamic Bone Disease (ABD) and Its Consequences on Bone Quality With Age [PhD thesis]. University of Toronto; 2015.